# Pauline Yang

> Pauline Yang is a Series C investor at Altimeter Capital backing SaaS. See 6 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [Altimeter Capital](https://shizune.co/investors/profile/altimeter-capital)
- Location: Menlo Park, United States
- Total investments: 6
- Last investment: Feb 2024
- Lead investor: 83%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/pauline-yang-9369891b/
- X (Twitter): https://x.com/paulinebhyang

Pauline Yang is a Series C investor at Altimeter Capital in Menlo Park focused on SaaS and Software. Pauline Yang is based out of San Francisco, California, and currently works as a Partner for Altimeter Capital.

## Contacts

5 contacts available for Pauline Yang: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/pauline-yang?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| SaaS | 2 | 33% |
| Software | 2 | 33% |
| Health Care | 2 | 33% |
| Life Science | 2 | 33% |
| Clinical Trials | 2 | 33% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 33% |
| Series D | 2 | 33% |
| Series B | 1 | 17% |
| Series E | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Unlearn.AI | Unlearn.AI is a biotech AI company that develops a digital twin service for clinical trials. Digital twins enhance healthcare by assessing health risks before a disease manifests its symptoms, according to some experts.  Unlearn brings together a world-class team of experts across pharma, medtech, machine learning, and business who share a visionof using machine learning and biostatistics to improve clinical trials for the benefit of patients and sponsors.Unlearn invented their TwinRCT solution to enable biopharma partners to run faster, more successful clinical trials. A TwinRCT is a randomized trial that uses machine learning to achieve a higher probability of success with a smaller number of patients. As in a traditional RCT, patients are randomized to a treatment group and a control group, but, unlike a traditional trial, a prognostic digital twin is created for every patient using a machine learning model trained on historical data. The treatment effects for the primary and secondary outcomes can all be estimated from the trial with greater precision after correcting for a prognostic score derived for each patient's digital twin.TwinRCTs provide a scientifically-sound method for using deep learning and historical patient data to improve clinical trials. | $50M | Series C | Feb 08, 2024 | https://www.unlearn.ai/ |
| Reify Health | Reify Health provides cloud-based software that helps accelerate the development of new, life-saving therapies. The company's system accelerates enrollment timelines and the overall pace of research, enabling research sponsors and coordinators to focus on the actions that impact clinical research success. Reify Health product StudyTeam is acloud-based software that helps clinical trial teams achieve faster, more predictable enrollment while eliminating the tedious work that saps productivity and study budget. It gives sponsors, CROs, and clinical research sites earlier visibility to the full enrollment picture, and the insight they need to focus on people and capital on work that yields the greatest return. | $220M | Series D | Apr 21, 2022 | http://www.reifyhealth.com |
| H1.co | H1 is an AI-powered platform that helps identify and engage the right doctors for critical workflows across pharma, health plan, health system, and technology companies. At the core of the platform is H1’s Doctor Graph—a structured representation of physician identity, expertise, relationships, and behavioral signals, creating a powerful networkeffect as it is continuously enriched by participants across the healthcare ecosystem. Built on one of the world’s largest and most comprehensive global datasets of healthcare professionals, H1 combines deep healthcare data with agentic AI workflows to power critical workflows across drug development, medical and commercial engagement, care navigation, and provider data and network intelligence. Founded in 2017, the company is based in New York, United States. | $100M | Series C | Nov 16, 2021 | https://www.h1.co |
| Workato | Workato is an intelligent automation platform designed to automate work in businesses. It enables business and IT to integrate their apps and automate complex business workflows with security and governance. It helps businesses create powerful, business-critical integrations between cloud apps in minutes. Founded on 2013, Workato is trusted bytop brands as well as its growing innovators. It is headquartered in Mountain View, California. | $200M | Series E | Nov 10, 2021 | http://www.workato.com |
| Workato | Workato is an intelligent automation platform designed to automate work in businesses. It enables business and IT to integrate their apps and automate complex business workflows with security and governance. It helps businesses create powerful, business-critical integrations between cloud apps in minutes. Founded on 2013, Workato is trusted bytop brands as well as its growing innovators. It is headquartered in Mountain View, California. | $110M | Series D | Jan 12, 2021 | http://www.workato.com |
| Transposit | Transposit delivers connected workflow for the digital enterprise. Its fully integrated, human-in-the-loop approach to automation gives TechOps and SREs visibility, context, and actionability across people, processes, and APIs. Transposit helps teams increase operational efficiency, simplify audit and compliance, and deliver a great customerexperience. As the glue between tools, data and people, Transposit codifies institutional knowledge to make processes data-driven and repeatable with Runbooks that help teams incrementally automate tasks. Transposit captures the complete history of all actions taken through a system and surfaces actionable insights that drive operational improvement. Powered by the Transposit Integration Engine that combines hundreds of pre-built integrations with code-level customization, the cloud-based platform is able to connect to any service with an API. Organizations rely on Transposit to improve workflow agility and keep services healthy so they can deliver more value to their business.Tina Huang established the company in San Francisco, California in 2016. | $35M | Series B | Sep 02, 2020 | https://www.transposit.com |

6 of 6 investments shown.

## Co-investors
- [Battery Ventures](https://shizune.co/investors/profile/battery-ventures) — VC Fund, 3 deals together
- [Insight Partners](https://shizune.co/investors/profile/insight-partners) — VC Fund, 3 deals together
- [IVP](https://shizune.co/investors/profile/institutional-venture-partners) — VC Fund, 3 deals together
- [Redpoint](https://shizune.co/investors/profile/redpoint-ventures) — VC Fund, 3 deals together
- [Menlo Ventures](https://shizune.co/investors/profile/menlo-ventures) — VC Fund, 2 deals together
- [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 1 deal together

## About Altimeter Capital

VC Fund · Menlo Park, United States

Altimeter Capital is a technology-focused investment firm based in Menlo Park, CA and Boston, MA. Altimeter manages a long/short public equity fund and growth-stage private capital funds.

5 contacts available at Altimeter Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Gwendolyn Umbach | Investor | https://shizune.co/investors/profile/gwendolyn-umbach |
| Jamin Ball | Partner | https://shizune.co/investors/profile/jamin-ball |
| Pauline Yang | Partner | https://shizune.co/investors/profile/pauline-yang |
| Brad Gerstner | Founder & CEO | https://shizune.co/investors/profile/brad-gerstner |
| John Kiernan | Chief Financial Officer and Partner | https://shizune.co/investors/profile/john-kiernan |

## Similar investors

### Similar stage
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund

## FAQ

### What does Pauline Yang invest in?

Pauline Yang invests primarily in SaaS, Software and Health Care startups, most often at Series C and Series D stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Pauline Yang?

Public channels for Pauline Yang include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Pauline Yang last invest?

The most recent investment recorded for Pauline Yang closed in Feb 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co